SCHEMBL12434247

SCHEMBL12434247

COc1ccc(NC(=O)NCc2ccccc2-c2ccccc2C(=O)NCc2cccnc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 1/20 0.65
KCNH2 Q12809 1/20 0.65
NAMPT P43490 12/20 0.64
GAA P10253 1/20 0.57
CRHBP P24387 1/20 0.55
CRHR2 Q13324 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KMT2A Q03164 2/20 0.54
HTT P42858 1/20 0.54
POLB P06746 1/20 0.54
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
HSD17B10 Q99714 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12434086 0.87 KCNK3 (0.84) KCNK3KCNH2GAAKMT2AHTT
SCHEMBL20379359 0.85 NAMPT (0.85) NAMPTGAACRHBPCRHR2L3MBTL1
SCHEMBL12335343 0.79 KMT2A (0.79) NAMPTL3MBTL1KMT2AHTTPOLB
SCHEMBL26099680 0.79 NAMPT (0.72) NAMPTCRHBPCRHR2L3MBTL1KMT2A
SCHEMBL30361464 0.79 NAMPT (0.72) NAMPTCRHBPCRHR2L3MBTL1KMT2A
SCHEMBL29778218 0.79 KCNK3 (1.00) KCNK3KCNH2GAAKMT2AHTT
SCHEMBL498292 0.79 KCNK3 (1.00) KCNK3KCNH2GAAKMT2AHTT
SCHEMBL12434243 0.79 KCNA5 (0.61) KCNK3KCNH2L3MBTL1KMT2APOLB
SCHEMBL12335432 0.79 NAMPT (0.50) KCNK3KCNH2NAMPTKMT2APOLB
SCHEMBL30361447 0.78 NAMPT (0.70) NAMPTCRHBPCRHR2L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNK3 346/4885KCNH2 51/4885NAMPT 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.